6 Meridian Purchases 76,219 Shares of Eli Lilly And Co (NYSE:LLY)

6 Meridian raised its position in Eli Lilly And Co (NYSE:LLY) by 97.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 154,822 shares of the company’s stock after buying an additional 76,219 shares during the period. Eli Lilly And Co accounts for about 1.8% of 6 Meridian’s investment portfolio, making the stock its 8th biggest position. 6 Meridian’s holdings in Eli Lilly And Co were worth $20,348,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in shares of Eli Lilly And Co by 0.8% during the second quarter. Vanguard Group Inc. now owns 71,134,378 shares of the company’s stock worth $7,880,977,000 after purchasing an additional 578,045 shares in the last quarter. BlackRock Inc. lifted its position in shares of Eli Lilly And Co by 1.5% during the second quarter. BlackRock Inc. now owns 61,979,145 shares of the company’s stock worth $6,866,670,000 after purchasing an additional 898,845 shares in the last quarter. Nuveen Asset Management LLC lifted its position in shares of Eli Lilly And Co by 20,030.9% during the second quarter. Nuveen Asset Management LLC now owns 7,265,844 shares of the company’s stock worth $804,983,000 after purchasing an additional 7,229,751 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Eli Lilly And Co by 10.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 6,442,803 shares of the company’s stock worth $720,499,000 after purchasing an additional 628,267 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. lifted its position in shares of Eli Lilly And Co by 13.2% during the second quarter. Amundi Pioneer Asset Management Inc. now owns 5,422,106 shares of the company’s stock worth $600,715,000 after purchasing an additional 632,573 shares in the last quarter. Hedge funds and other institutional investors own 76.45% of the company’s stock.

In other news, CFO Joshua L. Smiley bought 929 shares of the stock in a transaction on Friday, October 25th. The stock was purchased at an average price of $107.59 per share, with a total value of $99,951.11. Following the completion of the purchase, the chief financial officer now owns 31,524 shares of the company’s stock, valued at $3,391,667.16. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO David A. Ricks bought 4,615 shares of the stock in a transaction on Friday, October 25th. The stock was purchased at an average cost of $108.38 per share, with a total value of $500,173.70. Following the purchase, the chief executive officer now directly owns 157,405 shares of the company’s stock, valued at approximately $17,059,553.90. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 8,405 shares of company stock worth $909,004 and sold 1,575,504 shares worth $191,219,312. Corporate insiders own 0.11% of the company’s stock.

Shares of NYSE LLY opened at $138.94 on Tuesday. The company’s 50 day simple moving average is $126.70 and its 200 day simple moving average is $115.12. Eli Lilly And Co has a fifty-two week low of $101.36 and a fifty-two week high of $139.99. The firm has a market capitalization of $132.50 billion, a P/E ratio of 25.03, a P/E/G ratio of 1.80 and a beta of 0.20. The company has a debt-to-equity ratio of 4.09, a current ratio of 1.17 and a quick ratio of 0.88.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 23rd. The company reported $1.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.43 by $0.05. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The business had revenue of $5.48 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same period in the prior year, the business posted $1.39 earnings per share. Eli Lilly And Co’s revenue was up 3.2% compared to the same quarter last year. Sell-side analysts expect that Eli Lilly And Co will post 5.8 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 14th will be issued a $0.74 dividend. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.65. This represents a $2.96 annualized dividend and a yield of 2.13%. The ex-dividend date of this dividend is Thursday, February 13th. Eli Lilly And Co’s dividend payout ratio is currently 46.49%.

A number of brokerages have recently issued reports on LLY. Bank of America began coverage on shares of Eli Lilly And Co in a research report on Wednesday, October 16th. They set a “buy” rating and a $133.00 target price on the stock. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly And Co from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. Argus upped their target price on shares of Eli Lilly And Co from $145.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, December 30th. UBS Group reduced their target price on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating on the stock in a research report on Thursday, October 17th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $143.00 target price on shares of Eli Lilly And Co in a research report on Monday, December 2nd. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $135.67.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Dividend Stocks – Are They Right For You?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.